Stockscreener 앱 받기
4.01
0.50%
0.02
시장 영업 전:
4.11
0.10
+2.49%
전일 마감가:
$3.99
열려 있는:
$4.05
하루 거래량:
198.87K
Relative Volume:
1.53
시가총액:
$70.73M
수익:
$52.55M
순이익/손실:
$-23.69M
주가수익비율:
-4.266
EPS:
-0.94
순현금흐름:
$-15.29M
1주 성능:
+33.67%
1개월 성능:
-22.14%
6개월 성능:
+104.59%
1년 성능:
+102.53%
1일 변동 폭
$3.72
$4.20
1주일 범위
$2.76
$4.20
52주 변동 폭
$1.3003
$6.22
Exagen Inc Stock (XGN) Company Profile
명칭
Exagen Inc
전화
(760) 560-1501
주소
1261 LIBERTY WAY, VISTA, CA
XGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.01 | 70.73M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-05 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-04-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cowen | Outperform |
| 2019-10-14 | 개시 | William Blair | Outperform |
모두보기
Exagen Inc 주식(XGN)의 최신 뉴스
Exagen Gains 28%, Insider Trades Reap Benefit - Yahoo Finance
The 26% return this week takes Exagen's (NASDAQ:XGN) shareholders one-year gains to 102% - Simply Wall St
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? - MSN
Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests - Lupus Foundation of America
Exagen’s (XGN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reaffirms "Overweight" Rating for Exagen (NASDAQ:XGN) - MarketBeat
Exagen Inc. Secures Conditional NY State Approval for New - GlobeNewswire
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis - The Bakersfield Californian
Exagen Achieves Record $55.8M Revenue, Gets NY Approval for New Lupus & RA Biomarker Tests - StockTitan
Exagen (NASDAQ:XGN) Given New $7.00 Price Target at Canaccord Genuity Group - Defense World
Exagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Short Interest in Exagen Inc. (NASDAQ:XGN) Grows By 36.5% - Defense World
Exagen Inc. (NASDAQ:XGN) Short Interest Up 36.5% in December - MarketBeat
Exagen (NASDAQ:XGN) Stock Price Up 1.4%Time to Buy? - MarketBeat
Exagen (NASDAQ:XGN) Trading 1.4% Higher – Still a Buy? - Defense World
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - Simply Wall St
Learn to Evaluate (XGN) using the Charts - Stock Traders Daily
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewswire
Exagen Hits Major Milestone: 1 Million AVISE Tests Revolutionize Autoimmune Disease Diagnosis - StockTitan
Exagen stock soars to 52-week high, hits $4.97 - Investing.com
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com India
Exagen stock soars to 52-week high, hits $4.88 amid robust gains By Investing.com - Investing.com South Africa
Exagen stock soars to 52-week high, hits $4.88 amid robust gains - Investing.com Canada
Wasatch Advisors LP Sells 272,054 Shares of Exagen Inc. (NASDAQ:XGN) - MarketBeat
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Nigeria
Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada
Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St
Exagen stock soars to 52-week high, hits $3.79 - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK
Exagen president and CEO John Aballi buys $68,297 in stock By Investing.com - Investing.com Canada
Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com
What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exagen Inc (XGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
자본화:
|
볼륨(24시간):